Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JK1201I versus topotecan in relapsed or progressed extensive-stage small cell lung cancer
CTR20243174Phase 3Active
- Sponsor
- JenKem Technology
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of JK-1201I in small cell lung cancer (SCLC), sponsored by JenKem Technology. Started Oct 2024; status: active.
02
Drugs
JK-1201I
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20243174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243174.